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Abstract
Up to 20% of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) patients develop severe inflammatory
complications with diffuse pulmonary inflammation, reflecting acute respiratory distress syndrome (ARDS). A similar
clinical profile occurs in severe trauma cases. This review compares pathophysiological and therapeutic principles of
severely injured trauma patients and severe coronavirus disease 2019 (COVID-19).
The development of sequential organ failure in trauma parallels deterioration seen in severe COVID-19. Based on
established pathophysiological models in the field of trauma, two complementary pathways of disease progression
into severe COVID-19 have been identified. Furthermore, the transition from local contained disease into systemic
and remote inflammation has been addressed. More specifically, the traumatology concept of sequential insults
(‘hits’) resulting in immune dysregulation, is applied to COVID-19 disease progression modelling. Finally, similarities
in post-insult humoral and cellular immune responses to severe trauma and severe COVID-19 are described.
To minimize additional ‘hits’ to COVID-19 patients, we suggest postponing all elective surgery in endemic areas.
Based on traumatology experience, we propose that immunoprotective protocols including lung protective
ventilation, optimal thrombosis prophylaxis, secondary infection prevention and calculated antibiotic therapy are
likely also beneficial in the treatment of SARS-CoV-2 infections. Finally, rising SARS-CoV-2 infection and mortality
rates mandate exploration of out-of-the box treatment concepts, including experimental therapies designed for
trauma care.
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Background
Originating from the Wuhan Province in China, the
novel member of the coronoviridae family named Severe
Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-
2) has rapidly developed into a global pandemic [1, 2].
Given the rising infection and mortality rates that have
already or may soon overwhelm our critical care infra-
structure, out-of-the-box treatment concepts should im-
mediately be explored [3]. Up to 20% of SARS-CoV-2
infected patients develop severe inflammatory complica-
tions with diffuse pulmonary inflammation, reflecting
acute respiratory distress syndrome (ARDS) [4, 5]. Simi-
larly, a pattern of respiratory failure occurs in a sub-
group of severely injured trauma patients [6]. ARDS is a
frequent contributing factor towards morbidity and mor-
tality after trauma [7]. Indeed, a recent meta-analysis
demonstrates that the incidence of trauma-induced
ARDS has not changed over the last few decades or var-
ied between geographic regions [8].
Given their similar clinical profiles, there may be more
similarities between severe trauma and severe cases of
SARS-CoV-2 than might initially be assumed. In this re-
view, we will consider the notion that severe disease pro-
gression in SARS-CoV-2/Corona Virus Disease 2019
(COVID-19) patients mimics disease mechanisms that
occur in complicated courses of severe trauma.
There is a broad spectrum in clinical courses of both
severe trauma and severe illness caused by SARS-CoV-2
infection [4, 9–12]. Most cases present a mild or moder-
ate clinical course and prompt recovery occurs. How-
ever, in both conditions, a specific subgroup of about
20% of patients develop a complicated course character-
ized by an overwhelming inflammatory response
resulting in a life-threatening condition and high mortal-
ity [4, 10, 13, 14]. In both disease processes, the differ-
ence between a mild and severe clinical course depends
on the development of sequential organ failure. As in
trauma, this cascade typically starts with the develop-
ment of pulmonary failure: ARDS, sequentially leading
to multiple organ dysfunction syndrome (MODS) and
death [6, 14–17]. Documented mortality rates among in-
tensive care unit (ICU)-admitted COVID-19 patients
have to date ranged from 62 to 81% [4, 13, 18].
It is tempting to speculate that proven approaches and
even promising experimental therapies for severely in-
jured trauma patients can also play a role in the manage-
ment of critically ill COVID-19 patients. This review will
compare pathophysiology and treatment strategies be-
tween severe trauma and life-threatening SARS-CoV-2
infections.
Pathophysiology of severe trauma
In trauma, tissue damage activates the immune response,
with extensive tissue damage invoking systemic
inflammation [6, 15, 16]. Alterations in local and
systemic immune responses after severe trauma are
recognized as a physiological reaction to restore
homeostasis. The magnitude of these immunological
changes correlates with the degree of local and sys-
temic tissue damage [6, 19].
Necrotic cells rapidly release alarmins (Damage Asso-
ciated Molecular Patterns (DAMPs)), which are en-
dogenous molecules and are equivalent in function to
pathogen associated molecular patterns (PAMPs, e.g.
SARS-CoV-2 proteins). As their name suggests, alarmins
alert the immune system and their ultimate function is
to restore homeostasis by promoting regeneration of
damaged tissue [6, 16, 20, 21].
In trauma, various relevant alarmins have been identi-
fied and characterized. One such alarmin, High Mobility
Group Box 1 (HMGB1), has shown chemotactic effects
on monocytes, macrophages, and neutrophils, and is a
very potent stimulator of immune cell maturation [22].
In addition, Heat Shock Protein (HSP) interacts with
several receptors including toll-like receptors and stimu-
late the secretion of proinflammatory cytokines such as
tumor necrosis factor (TNF)-α and interleukin (IL)-1β
[23]. These cytokines are early regulators of the pro-
inflammatory immune response to trauma, and both of
them induce the release of secondary cytokines, such as
IL-6 and IL-8 [6, 24]. These cytokines, which are pre-
dominantly produced by monocytes and macrophages,
mediate a variety of frequently overlapping effects, and
their actions can be additive [6, 24]. DAMPS and cyto-
kines further activate different immune cells including
neutrophils and monocytes via DAMP-receptors [25].
The balance and interplay of these different endogen-
ous molecules dictates the clinical course in trauma pa-
tients. Overexpression of either pro-inflammatory or
anti-inflammatory mediators may induce organ dysfunc-
tion. Whereas a predominantly pro-inflammatory re-
sponse leads to the systemic inflammatory response
syndrome (SIRS), a predominantly anti-inflammatory
reaction leads to the compensatory anti-inflammatory
response syndrome (CARS). In the absence of inflamma-
tory complications, concurrent SIRS/CARS responses
should be considered a physiological process and bal-
ance each other out. However, excessive SIRS can result
in immune overreaction, while CARS may lead to im-
mune suppression or paralysis, with a subsequent in-
creased risk of infectious complications [6, 16, 20, 21].
Interestingly, in severe blunt trauma, it has been demon-
strated that the early immune response is consistent
with simultaneously increased expression of both pro-
inflammatory genes (SIRS-response) and anti-
inflammatory genes (CARS-response) [26]. Together,
this response induces an increase in circulating cytokines
resulting in a cytokine storm [27]. Moreover, the
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development of systemic inflammatory complications,
such as organ failure, are associated with the magni-
tude and duration of a genomically induced cytokine
storm [20, 21, 24, 26, 27].
Extrapulmonary inflammatory processes affect the pul-
monary compartment via the circulatory uptake of these
cytokines [6, 28]. One crucial step in the pathophysi-
ology of distant organ damage is the adherence of
activated polymorphonuclear leukocytes to capillary
endothelial cells [29]). This is characterized by leukocyte
diapedesis in organ tissue, with subsequent release of
oxygen radicals and proteases [30]. These consequently
damage the endothelial layer, resulting in increased ca-
pillary permeability, interstitial oedema and finally dis-
tant organ damage [6, 9, 16, 30]. Further inflammatory
activation causes local collateral damage to parenchymal
cells and result in subsequent lung dysfunction [6, 15,
16, 31]. The collaboration of humoral immune factors
and immune cells play an essential role in the transition
from an appropriate to an overwhelming, dysregulated
immune response [6, 15, 16, 31, 32].
These pathophysiological inflammatory cascades result
in significant changes in the anatomy, mechanics and
function of the lung [33]. An initial increase in pulmon-
ary capillary permeability stimulates alveolar flooding
and oedema. The consequence is the loss of surfactant
function. This causes atelectasis and subsequent alveolar
instability, resulting in repetitive alveolar collapse and
expansion, and finally impaired gas exchange with local
and systemic hypoxia [32, 33].
Pathophysiology of severe COVID-19
The exact pathophysiology of SARS-CoV-2 infection, and
more specifically its considerable capacity to extensively
disturb physiological homeostasis, is currently unclear.
However, based on recent clinical and experimental find-
ings and related viral diseases such as Severe Acute
Respiratory Syndrome Coronavirus 1 (SARS-CoV-1), basic
understanding has rapidly increased. The current SARS-
CoV-2 virus, as well as the SARS-CoV-1 and the Middle
East Respiratory Syndrome Coronavirus (MERS-CoV) are
related pathological human coronaviruses (CoVs) [34–36]
Phylogenetic studies show an 80% nucleotide identity of
SARS-CoV-2 with SARS-CoV-1 and the pathophysio-
logical insights made for SARS-CoV-1 can likely be ap-
plied to SARS-CoV-2 [37, 38].
In line with SARS-CoV-1, the angiotensin-converting
enzyme 2 (ACE2), a type I membrane protein, is consid-
ered the host cell surface-receptor for the SARS-Cov-2
spike receptors [39, 40]. Kuba et al. demonstrated the
key role of ACE2-receptors in SARS-CoV-1 pathology
by showing that ACE2-KO mice were unsusceptible to
SARS-CoV exposure [41]. Distribution of the ACE2-
receptor is tissue specific, and varying degrees of
receptor expression are seen in lungs (type I and type II
alveolar epithelial cells as well as bronchiolar epithelial
cells), heart, kidneys and the gastro-intestinal tract [42,
43]. Tissue specific ACE2-receptor distribution patterns
may affect disease progression and make specific organs
more susceptible. This is supported by histopathological
studies of SARS-CoV fatalities showing most prominent
tissue damage in the respiratory system with less exten-
sive damage to liver, kidney, cardiac and digestive tract
tissues [44, 45].
ACE2 plays an important physiological role in regulat-
ing blood pressure via the renin-angiotensin-aldosterone
system (RAAS). It is therefore tempting to hypothesize
that there is an interplay between clinical observations
linking hypertension with impaired outcome in SARS-
Cov-2 infection [46, 47]. Upon viral cell invasion, how-
ever, the process leading to end-organ parenchymal cell
destruction and finally resulting in life threatening com-
plications such as ARDS and MODS remain unclear.
SARS-CoV-1 mice models demonstrated the relevance
of ACE2-expression and suggests that SARS-CoV may
directly derange ACE2-lung protective pathways [48].
In addition to these direct pathophysiological pro-
cesses of SARS, it is likely that other indirect processes
also play a critical role in the rapid progression of severe
COVID-19. The SARS-CoV-1 epidemic emphasized this
with the observation that disease progression into crit-
ical stages was commonly associated with diminishing
viral titers [34, 49]. Studies on the association between
viral load and COVID-19 disease severity, however, are
scarce, and have so far demonstrated conflicting results
[50, 51]. Post-mortem observations in SARS-CoV-1 and
SARS-CoV-2 are characterized by alveolar exudative in-
flammation, interstitial inflammation, alveolar epithelial
proliferation, and hyaline membrane formation, thereby
demonstrating ARDS-like lesions [4, 5, 52–54].
From an immunological perspective, a prominent neu-
trophil and macrophage presence was observed in the pul-
monary interstitium and alveoli in SARS-CoV-1 fatalities
[54]. The aberrant systemic cellular immune response of
fatal SARS-CoV-1-cases was characterized by both an in-
crease in circulating monocytes and neutrophils and a re-
duction in circulating lymphocytes [55, 56].
In SARS-CoV-2, lymphopenia is common [4, 12] and
both circulatory lymphopenia and leukocytosis are asso-
ciated with COVID-19 mortality [10]. In contrast with
mild cases of COVID-19, a reduction of circulatory
CD4+ and CD8+ cells was observed in severe COVID-
19 infection [57, 58].
In addition to an altered cellular immune response in
fatal SARS-CoV-1/2 infections, transient humoral dys-
regulation has also been described. Whereas minimal
cytokine level alterations are seen in mild COVID-19 in-
fection [57], severe infections have shown elevated levels
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of pro-inflammatory cytokines including TNF-alpha, IL-
6, IL-10 [58].
Although experimental clinical data on COVID-19 in-
fection is scarce, the presence of an aberrant humoral
immune response is further suggested by significantly in-
creased serum IL-6 levels found in COVID-19 fatalities
[59, 60]. Moreover, a cytokine storm, indicative of wide-
spread immune activation similar to that found in post-
traumatic ARDS, has also been observed in SARS-CoV-2
infection [26, 59–61].
Based on these findings, it is tempting to hypothesize
that rather than direct cytotoxic effects of virus-infected
cells alone, severe SARS-CoV-2 infection triggers both
the humoral and cellular immune system. Consequent
life-threatening complications therefore primarily relate
to an aberrant immune response. A similar aberrant im-
mune response after severe trauma has been well estab-
lished. The pathophysiological mechanisms observed in
trauma may be universal and are therefore likely also in-
volved in COVID-19 disease progression. Insights in the
pathophysiology of severe trauma may therefore form
the basis for novel therapeutic concepts for SARS-CoV-
2 and we propose the pathophysiological model of
COVID-19 disease progression as being displayed as
Fig. 1.
This figure summarizes the process of ongoing inflam-
mation, starting from insult (viral infection), into the de-
velopment of end-organ inflammation and dysfunction.
The initial insult evokes a local systemic response in-
cluding involvement of natural killer cell/dendritic cells,
lymphocytes, neutrophils and macrophages. Adequate
responses result in viral clearance and in the case of
contained local infection, minimal collateral damage to
parenchymal organ cells and consequent recovery. How-
ever, in case the immune response is unable to stop
ongoing viral replication, disease progression may occur.
Based on the pathophysiological concepts in SARS-CoV-
1, SARS-CoV-2 and trauma summarized above, it is
tempting to hypothesize that COVID-19 disease progres-
sion is based on two primary mechanistic pathways.
These pathways are a direct (PAMP-driven) pathway
and an indirect (DAMP-driven) pathway, either of which
can lead to COVID-19 disease progression:
(i) A direct (‘PAMP’)-driven pathway. This is
characterized by increased local spread of the virus
and eventually dissemination of viral infection
(dependent on tissue-specific ACE2-receptor ex-
pression levels and likely correlating with increased
viral load). Vital organ involvement may occur, even
Fig. 1 Sequential thresholds in virus-evoked inflammation. A hypothetical multifactorial model of disease progression in COVID-19 is presented.
Two specific pathways have been described, and an interplay is likely to occur. At all phases restoration of homeostasis is possible and will lead
to recovery. The development of differentiated treatment concepts may benefit from this model, guide tailored interventions at different stages
of disease progression. Abbreviations: ALI, acute lung injury; ARDS, acute respiratory distress syndrome; PAMPs, pathogen associated molecular
patterns; DAMPs, damage associated molecular patterns
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in the absence of initial systemic inflammation,
leading to (multiple) organ dysfunction.
(ii) An indirect (‘DAMP’)-driven pathway. Upon
contained local inflammation, a secondary massive
immune response may be initiated (including a
cytokine storm, large-scale innate immune cell acti-
vation and SIRS/CARS-responses). These processes
lead to extensive systemic inflammation and subse-
quent altered homeostasis of vital organs. Finally,
organ failure may occur due to inflammation-
induced collateral damage in end-organs. Progres-
sion according to this pathway is independent of
viral load.
These are not mutually exclusive pathways, and inter-
play between these may potentially play a role in the
progression of COVID-19. At all phases of both path-
ways, improvement and restoration of homeostasis is
possible and will lead to recovery.
First and second hit mechanism in severe trauma and
COVID-19
‘First hit’
In traumatology, the term ‘first hit’ is used to describe
the initial insult condition, or trauma, the patient faces.
The intensity of the first hit is based on the trauma load:
the degree of initial tissue damage, including organ in-
jury, fractures, burn injury, soft tissue injury, and hypo-
volemic shock. Consequently, local and systemic release
of both pro-inflammatory and anti-inflammatory media-
tors is dependent on the severity of the first hit of the
trauma itself [62]. These insults determine the initial
trauma load and result in activation of the innate and
adaptive immune system that stimulate the local and
systemic inflammatory reactions. Moreover, genetic pre-
disposition seems to affect the immune response as well
[6]. The subsequent activation of immune cells (poly-
morphonuclear granulocytes, monocytes and lympho-
cytes) trigger multifocal processes leading to tissue
regeneration and repair. Excessive tissue damage,
however, may magnify the extent of local and systemic
activation leading to organ dysfunction. Whereas a
predominantly pro-inflammatory response leads to an
excessive SIRS-response, a predominantly anti-
inflammatory reaction may result in an intensified
CARS-response and with subsequent immunoparalysis
and a consequent increased risk of infectious complica-
tions [6, 15, 16].
Similarly, with COVID-19, the first hit is the initial
viral infection itself, centred primarily on respiratory tis-
sue. The magnitude of the first hit is associated with
predisposing factors (e.g. sex, expression of ACE2 recep-
tors) and viral load. Existing comorbidities may also
affect the severity of the initial insult and determine the
overall impact of the first hit on homeostasis. Patients
with diabetes, cardiovascular disease, hypertension and
lung disease are especially prone to decompensation in
SARS-CoV-2 infection [4, 12].
‘Second hit’
In trauma cases, the secondary activation of various mo-
lecular cascades due to an additional insult are known as
second hit- phenomena. This secondary immune cell ac-
tivation, or priming, is stimulated by a variety of triggers
[6, 15, 16, 31]. These triggers may be iatrogenic (e.g.
mechanical ventilation [63], surgical intervention [20,
21], transfusions) or non-iatrogenic (e.g. secondary in-
fection [64], thromboembolic complications [65], ische-
mia/reperfusion injury [66]. Each insult further catalyses
the immune response, and depending on severity may
cause an excessive inflammatory response. This process
initiates a vicious cycle of local tissue damage, addition-
ally aggravated by systemic hyperactivation ultimately
leading to a life-threatening, overwhelming immune
response.
Similarly, in severe COVID-19 infection, secondary in-
sults or complications may stimulate an exaggerated im-
mune response, amplify systemic inflammation, or at a
later stage induce immune paralysis. Respiratory distress
and systemic hypoxemia may stimulate further tissue in-
jury and abruptly require intensive care and monitoring.
In addition, metabolic decompensation and systemic hy-
poperfusion are further risk factors associated with re-
mote tissue damage. Secondary pulmonary bacterial
infections or catheter-associated infections are further
potential second hit events, all of which are capable of
aggravating the clinical course of the disease. Figure 2
displays our proposed model of consecutive insults and
systemic inflammatory disease progression in COVID-
19, based on established trauma models. Like trauma,
viral infection causes rapid activation of the immune sys-
tem. In case the first hit insult is potent enough, sys-
temic inflammation occurs. Upon initiation of systemic
inflammation, both a systemic inflammatory response
syndrome (SIRS) and a compensatory anti-inflammatory
response syndrome (CARS) are evoked. The green
curves in Fig. 2 represent uncomplicated courses and
lead to recovery. In these courses, the inflammatory re-
sponse is considered a physiological process.
In some patients, however, immune dysregulation oc-
curs. Excessive immune activation (hyperactivation, red
curves in Fig. 2) may occur, and collateral damage to
parenchymal cells of vital organs may lead to organ fail-
ure or multiple organ dysfunction syndrome (MODS).
Alternatively, patients may develop inflammatory com-
plications due to immune paralysis as a result of CARS.
A refractory state of the immune system is incapable of
resolving the SARS-CoV-2 infection and are more
Teuben et al. Patient Safety in Surgery           (2020) 14:28 Page 5 of 10
susceptible to novel pathogens. Complications develop
when either the primary viral or secondary microbial in-
fection cannot be resolved. Eventually, infection-related
MODS may occur (blue curves in Fig. 2). In both cases,
additional hits may push a patient from a physiological
immune response to either a pathological hyperinflam-
matory immune response or a pathological hypo-
inflammatory immune response.
Potential treatment strategies for severe COVID-19
disease
Numerous fast-tracked clinical trials to treat COVID-19
infections have recently been initiated. Many therapeutic
strategies focus primarily on inhibiting the virus, or bol-
stering the immune system. These strategies are aimed
at treating the direct PAMP-driven pathophysiological
pathway, thereby supporting the immune response.
Based on experience treating ARDS in trauma, trying
to do more may in fact be less. The majority of these ex-
perimental treatments may be focusing on the wrong
enemy: the virus, instead of the hosts’ uncontrolled im-
mune response. Alternatively, as in trauma, anti-
inflammatory interventions to modulate the hyperactive
immune response in COVID-19 may be promising. Most
modern treatment modalities for trauma are aimed at
the indirect DAMP-driven pathway, and to dampen sec-
ond hit events. Applying these concepts to COVID-19
treatment, the following measures complementary to
current treatment guidelines for COVID-19 disease
should be considered:
1. postponing all elective, non-essential surgical inter-
ventions in endemic areas. This has already been
adopted by many clinicians treating COVID-19 and
should be universally adopted. Furthermore, execu-
tion of invasive diagnostic procedures and interven-
tions should be limited to live-saving interventions
only.
2. lung-protective ventilation protocols to prevent a
barotrauma second hit [67]. Mechanical ventilation
when improperly used can exacerbate lung damage
by causing secondary ventilatory induced lung
injury (VILI). VILI can be significantly reduced with
proper positive end-expiratory pressure (PEEP)
levels to minimize atelectasis [67]. Moreover, lower-
ing tidal volume (Vt) and plateau pressure (Pplat)
may prevent lung over-distension. Alveolar strain
can be decreased by reducing the transpulmonary
pressure (Ptp) gradient [68].
3. sufficient thrombosis prophylaxis to prevent
thromboembolic second hits. In cases where
medicinal prophylaxis is contraindicated,
mechanical measures including compression
stockings or intermittent pneumatic compression
should be considered. Further, several studies have
described a close link between thrombogenesis and
Fig. 2 Proposed model of consecutive insult conditions and systemic inflammatory disease progression in COVID-19, based on established
trauma modelling. Established concepts in the field of severe trauma and related inflammatory complications have been applied to COVID-19
disease progression. Systemic inflammation may contribute to the restoration of homeostasis and should be considered a physiological process.
However, altered inflammatory response may lead to hyperinflammation or a pathological hypo-inflammatory immune response. See text for
details and explanations. Abbreviations: SIRS, systemic inflammatory response syndrome; CARS, compensatory anti-inflammatory
response syndrome
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inflammation. Proinflammatory cytokines (e.g. IL-6)
stimulate the expression of prothrombotic mediators.
Dampening the proinflammatory immune response
may further minimize the risk of thromboembolic
complications [69]. Increased serum D-dimer levels
in severe cases of COVID-19 and the frequent occur-
rence of embolic complications underline the rele-
vance of impaired thromboembolic homeostasis in
the specific case of COVID-19 [70].
4. transfusion of blood products should be minimized
to avoid transfusion induced immune activation and
more specifically transfusion-related acute injury
(TRALI)-like conditions [71].
5. prevent and treat secondary infections adequately to
prevent additional infectious insults and
inflammatory exaggeration. We suggest actively
searching for secondary infections by serial clinical
examination and routine laboratory analysis of
infection parameters. Additionally, catheter
associated infections can be minimized with regular
renewal schedules of catheters [72].
Table 1 provides an overview of standard measures
used to optimize care of critically ill trauma patients that
can be applied to severe SARS-CoV-2 infections. As a
next step, experimental immunomodulatory therapies
aimed to optimize outcomes of trauma induced inflam-
matory complications may be considered for the treat-
ment of SARS-CoV-2. Potential therapies include tissue
plasminogen activator (tPA) [73], the anti-inflammatory
effects of tranexamic acid [74], and extracorporeal cyto-
kine adsorption therapy [75].
Conclusion
This review attempts to draw analogies to pathophysio-
logical and therapeutic principles between severely in-
jured trauma patients and COVID-19. Many similarities
between both conditions have been identified, support-
ing the hypothesis that treatment concepts for ARDS in
trauma may potentially be of use in the management of
COVID-19. Two complementary pathways of disease
progression into severe COVID-19 have been identified
and described. Based on established pathophysiological
concepts in the field of trauma, we strongly suggest
postponing all elective surgery in endemic areas. Immu-
noprotective protocols such as lung protective ventila-
tion, adequate thrombosis prophylaxis, prevention of
secondary infection, and calculated antibiotic therapies
used to minimize inflammatory complications in trauma
patients are likely beneficial in the management of
SARS-CoV-2 infections, and should be universally ap-
plied whenever possible. Finally, experimental immuno-
modulatory interventions currently being investigated in
the setting of severe trauma may play a role in the man-
agement of COVID-19 patients and should be
investigated.
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- Calculated anti-infective therapies
- Frequent clinical examination to identify concurrent infection
- Frequent determination of serum inflammatory markers
- Routine renewal of urine and central catheters
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